AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have announced a collaboration ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...